Researchers trained a machine-learning model to estimate a person’s ‘brain age’ from overnight EEG recordings in roughly 7,000 adults, then compared that estimate to their actual age. People whose brains appeared older than expected on this scale had substantially higher rates of later dementia diagnosis. Each additional decade of estimated brain aging was linked to nearly a 40% increase in dementia risk. Because the tool relies on routine sleep EEG rather than expensive imaging, researchers hope it could become a low-cost early screening signal. This is an association found in observational data, not a trial testing whether acting on the score changes outcomes.

Focused ultrasound can temporarily open the blood-brain barrier, the tight seal that normally blocks drugs from reaching brain tissue, in patients with gliomas. Researchers showed this opening can be tuned to the size and location of a tumor, potentially letting chemotherapy or other targeted drugs reach areas usually shielded from them. Gliomas appeared more receptive to this controlled disruption than expected. The ultrasound itself doesn’t kill tumor cells; it’s a delivery method meant to work alongside existing or future drug therapies. This remains early-stage clinical research rather than an established treatment.

A research team in Britain and Spain studied what happens to the brain’s normal protective systems in the hours right after glioblastoma surgery. They identified a brief window when the brain’s usual barriers and immune surveillance are temporarily disrupted, which could either help leftover tumor cells or create an opportunity to deliver targeted treatments precisely when the brain is most receptive. The strategy under investigation is to exploit this narrow post-surgical period to reach microscopic tumor cells that survive even a complete-looking resection. Glioblastoma almost always recurs because these residual cells remain behind after surgery. The work describes a possible strategy at an early research stage, not a finished treatment.

Researchers built an artificial intelligence system designed to detect and classify brain tumors from MRI scans. In testing, the system reportedly identified and categorized tumors more accurately than conventional diagnostic approaches. These tools typically learn patterns from large sets of previously interpreted scans, then flag suspicious regions and suggest a likely tumor type. Better automated detection could help radiologists catch smaller or less obvious tumors sooner and reduce diagnostic delay. As with most AI imaging tools, it still needs independent validation across different scanners and patient populations before becoming part of routine care.

A study published in the journal Neurology compared ALS rates among male veterans across different branches of the U.S. military. Compared with Army veterans, men who served in the Air Force, Navy, and Coast Guard had higher rates of ALS, while Marine veterans had lower rates. Military service in general has long been linked to elevated ALS risk, though the underlying reasons remain unclear. This new analysis suggests the specific branch of service may matter, pointing toward possible differences in environmental or occupational exposures. The findings are observational and don’t yet pin down a specific cause.

Researchers at USC’s Stevens Neuroimaging and Informatics Institute and Rancho Los Amigos National Rehabilitation Center have received an NIH grant to study why urinary incontinence commonly develops after stroke. The condition affects many stroke survivors but is often overlooked compared with more visible effects like limb weakness or speech difficulty. The team plans to examine which brain changes after stroke disrupt normal bladder control. This announcement covers new funding for future work, not results from completed research.

New blood tests that detect biological markers of Alzheimer’s disease are becoming available for people with Down syndrome, a population at very high risk of developing the disease at a young age. These tests offer a less invasive alternative to brain scans or spinal taps, which have traditionally been required for a definitive diagnosis. Because people with Down syndrome nearly always develop Alzheimer’s-related brain changes if they live long enough, earlier and easier detection could help families and doctors plan care sooner. The tests measure specific proteins tied to amyloid and tau buildup in the brain. This is a diagnostic advance, not a treatment, and it doesn’t change what options exist once the changes are confirmed.

Researchers studying the APOE2 gene variant, which is already linked to unusually long lifespans, found it appears to help brain cells repair DNA damage and recover from cellular stress more effectively than the common APOE3 or the risk-raising APOE4 variant. The work was done in cell and animal models, not in Alzheimer’s patients directly. The hope is that understanding exactly how APOE2 protects neurons could eventually lead to drugs that mimic its effects in people who carry the higher-risk APOE4 variant. This is basic biology at this stage, aimed at explaining a genetic pattern scientists have observed for years rather than testing a treatment.

Two research groups looked at the genetics of ‘SuperAgers,’ older adults who maintain the memory of people decades younger, expecting to find they simply inherited fewer Alzheimer’s risk genes. Instead, their APOE status and overall genetic risk scores looked essentially the same as typical older adults with average memory. That means whatever protects SuperAgers from age-related memory decline is not written in their DNA in any way researchers have yet identified. The real explanation may involve some combination of brain structure, lifestyle, health history, and environment that has not been pinned down

In a study of the psychedelic compound psilocybin, researchers measured brain activity before and after a single dose and found changes that persisted for up to a month, along with possible structural changes on brain imaging. Participants whose brain activity became more flexible and varied after the dose were more likely to report personal insight and, later, improvements in general well-being. The study is small and cannot say whether these brain changes caused the reported benefits or simply accompanied them. It adds to a growing body of early human research on psilocybin, but it is not evidence that the drug is an approved or proven treatment for any condition.

A study of roughly 1,700 adults found that people who watched television very frequently in midlife later showed smaller brain regions involved in memory, decision-making, and visual processing, along with more white matter damage on brain scans. Interestingly, simply sitting for long periods did not show the same association, suggesting something about the passive, engaged nature of heavy TV viewing specifically may matter. This is an observational study, so it cannot prove that television watching itself shrinks the brain rather than reflecting other habits common among heavy viewers. The researchers are careful to frame this as a link worth investigating further, not a settled cause-and-effect finding.

A large study, described as the biggest of its kind, found that people with long-term exposure to road traffic noise had a higher risk of developing Parkinson’s disease, with roughly a 3% increase in risk for every 11.5 decibel rise in noise levels. Parkinson’s is a progressive disease in which brain regions controlling movement and balance gradually deteriorate. The study is observational, meaning it shows an association between noise exposure and Parkinson’s risk but cannot prove that noise itself causes the disease. Researchers suspect chronic noise-related stress and disrupted sleep could plausibly contribute to neurological harm over decades, but the underlying mechanism remains unproven.

At a neurointerventional surgery meeting, researchers presented an early technique that delivers medication directly through the arteries supplying painful areas of the spine, aiming to treat severe chronic back pain, which is a leading cause of disability and opioid use. The approach is a newer application of catheter-based techniques already used elsewhere in the body, adapted specifically for spinal pain. Details presented were from an early clinical experience rather than a large randomized trial, so effectiveness and safety over the long term are not yet established. If it pans out, it would offer an alternative pathway for patients who have not responded to physical therapy, injections, or standard surgery.

Scientists at the University of Virginia Comprehensive Cancer Center have developed an experimental strategy targeting glioblastoma, the most common and deadliest primary brain cancer, which has resisted most treatment advances for decades. The approach is described as promising in early laboratory testing, though details on how far it has progressed toward human trials were limited. Glioblastoma remains notoriously difficult to treat because tumor cells infiltrate healthy brain tissue diffusely and because the blood-brain barrier limits how well many drugs reach the tumor. Any new laboratory strategy for this disease is worth tracking, but the history of glioblastoma research is full of promising early findings that did not survive the jump to human patients.

A study presented at a neurointerventional surgery meeting found that stroke patients who already had moderate-to-severe disabilities before their stroke are frequently excluded from endovascular thrombectomy, the procedure that mechanically removes a blood clot causing a large vessel occlusion stroke. The researchers found that many of these excluded patients might still gain meaningful benefit from the procedure, despite the field’s general caution about offering it to people with pre-existing disability. This is a real-world outcomes analysis rather than a randomized trial specifically enrolling disabled patients, so causal conclusions are limited. The findings raise the question of whether current selection criteria for thrombectomy are too conservative for a substantial group of patients.

A clinical trial based in Lund, Sweden has demonstrated that transplanting dopamine-producing cells derived from stem cells into the brain is feasible in people with Parkinson’s disease. The approach aims to replace the dopamine-producing neurons that are progressively lost in Parkinson’s, rather than just managing symptoms with medication. This is an early-stage trial focused on safety and feasibility, not a definitive test of whether the treatment improves symptoms long term. Parkinson’s researchers have pursued cell replacement strategies for decades with mixed results, so feasibility data is a meaningful but modest step.

Surgeons report successfully using robot-assisted techniques to drain multiple abscesses located deep within the brain, a location that is difficult and risky to reach with conventional surgical approaches. Deep brain abscesses can become life-threatening quickly if not treated, and traditional surgery in these areas carries higher risk of damaging surrounding tissue. The robotic guidance allowed more precise, less invasive access to multiple abscess sites in the same patients. This report describes clinical cases rather than a large controlled trial, but it demonstrates a practical use of surgical robotics for a genuinely difficult problem.

A group of specialists has released updated consensus guidance for diagnosing and managing prolactinomas, the most common type of hormone-secreting pituitary tumor. These tumors overproduce prolactin, which can cause irregular periods, infertility, unexpected milk production, and vision problems if the tumor grows large enough to press on nearby nerves. Most prolactinomas are treated successfully with medication rather than surgery, though surgery remains an option for tumors that don’t respond or grow despite treatment. The updated guidance reflects newer evidence on when to escalate treatment and how to monitor patients over time.

Yale scientists identified two proteins on the surface of neurons that appear to help a toxic protein associated with Parkinson’s disease move from cell to cell in the brain. In mouse experiments, blocking these two proteins significantly slowed the spread of disease. Parkinson’s is thought to progress in part because misfolded alpha-synuclein protein travels between neurons, gradually recruiting more of the brain into the disease process. This finding offers a specific new molecular target that could eventually be blocked with a drug, though this remains animal research at this stage.

Researchers found that blocking a protein called ZFP384 prolonged the brain’s natural repair processes after stroke in animal experiments. The brain has a limited window after a stroke during which it can rewire and partially compensate for damaged areas, and this window typically closes within weeks. By interfering with ZFP384, the researchers extended this repair period, allowing more recovery time in their animal model. The work points to a possible new drug target for stroke rehabilitation, but it has not yet been tested in humans.

A clinical study found that a purified oral formulation combining THC and CBD significantly and quickly reduced severe agitation in patients with late-stage, end-of-life dementia. Agitation is one of the most distressing symptoms for both patients and families in advanced dementia, and current treatment options are limited and often only modestly effective. The study used a specialized, standardized oil formulation rather than over-the-counter cannabis products, which matters for both dosing and safety. This appears to be a real clinical trial with a therapeutic effect, though details on trial size and duration of the studied population matter for how broadly it applies.

Congenital cerebral ventriculomegaly is a condition where the fluid-filled chambers in a fetus’s brain become enlarged, often as a form of hydrocephalus, and can affect brain development if untreated. Researchers report that detecting the condition early during pregnancy and treating it promptly after birth can help prevent developmental and neurological disabilities in affected infants. This isn’t a new treatment so much as an argument for earlier, more consistent prenatal screening and faster postnatal intervention. Hydrocephalus in infants is typically managed with shunt placement or newer minimally invasive procedures to relieve pressure and preserve normal brain development.